MX2008011289A - Composiciones que comprenden quitosano conveniente para tratamiento terapeutico integral o prevencion integral del sindrome metabolico. - Google Patents
Composiciones que comprenden quitosano conveniente para tratamiento terapeutico integral o prevencion integral del sindrome metabolico.Info
- Publication number
- MX2008011289A MX2008011289A MX2008011289A MX2008011289A MX2008011289A MX 2008011289 A MX2008011289 A MX 2008011289A MX 2008011289 A MX2008011289 A MX 2008011289A MX 2008011289 A MX2008011289 A MX 2008011289A MX 2008011289 A MX2008011289 A MX 2008011289A
- Authority
- MX
- Mexico
- Prior art keywords
- chitosan
- metabolic syndrome
- compositions
- conditions
- sub
- Prior art date
Links
- 208000001145 Metabolic Syndrome Diseases 0.000 title claims abstract description 43
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title claims abstract description 43
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 230000002265 prevention Effects 0.000 title claims abstract description 21
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 16
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- 230000036772 blood pressure Effects 0.000 claims description 11
- 239000008103 glucose Substances 0.000 claims description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 229960005070 ascorbic acid Drugs 0.000 claims description 7
- 235000010323 ascorbic acid Nutrition 0.000 claims description 7
- 239000011668 ascorbic acid Substances 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 150000003626 triacylglycerols Chemical class 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 235000006708 antioxidants Nutrition 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 3
- 125000005262 alkoxyamine group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 1
- 239000007870 radical polymerization initiator Substances 0.000 abstract 1
- 238000010526 radical polymerization reaction Methods 0.000 abstract 1
- 230000007170 pathology Effects 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000032928 Dyslipidaemia Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 241001580017 Jana Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000384A ITMI20060384A1 (it) | 2006-03-03 | 2006-03-03 | Composizioni comprendenti chitosano atte al trattamento terapeutico complessivo o alla prevenzione complessiva della sindrome metabolica |
| PCT/EP2007/052023 WO2007099170A1 (en) | 2006-03-03 | 2007-03-02 | Compositions comprising chitosan suitable for comprehensive therapeutic treatment or comprehensive prevention of the metabolic syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2008011289A true MX2008011289A (es) | 2009-01-27 |
Family
ID=38019452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008011289A MX2008011289A (es) | 2006-03-03 | 2007-03-02 | Composiciones que comprenden quitosano conveniente para tratamiento terapeutico integral o prevencion integral del sindrome metabolico. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9050356B2 (https=) |
| EP (1) | EP1996207B1 (https=) |
| JP (1) | JP5557451B2 (https=) |
| ES (1) | ES2392551T3 (https=) |
| IT (1) | ITMI20060384A1 (https=) |
| MX (1) | MX2008011289A (https=) |
| PL (1) | PL1996207T3 (https=) |
| WO (1) | WO2007099170A1 (https=) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54148090A (en) | 1978-05-11 | 1979-11-19 | Ajinomoto Co Inc | Peroral cholesterol-depressant |
| US4223023A (en) | 1978-10-12 | 1980-09-16 | Ivan Furda | Nonabsorbable lipid binder |
| JP2614297B2 (ja) * | 1988-12-27 | 1997-05-28 | 三栄源エフ・エフ・アイ株式会社 | ソーマチンの凝集・分離防止及び甘味改善法 |
| JPH04108734A (ja) | 1990-08-29 | 1992-04-09 | Kurita Water Ind Ltd | 降コレステロール剤 |
| JP2667351B2 (ja) * | 1992-03-24 | 1997-10-27 | 麒麟麦酒株式会社 | 食餌脂質消化吸収阻害剤および飲食品 |
| JP2507907B2 (ja) | 1992-06-08 | 1996-06-19 | 水産庁長官 | 血圧降下用の食品添加物質および抗高血圧剤 |
| US5550019A (en) * | 1993-05-26 | 1996-08-27 | La Jolla Cancer Research Foundation | Methods of identifying compounds which alter apoptosis |
| US6180148B1 (en) | 1996-05-28 | 2001-01-30 | Asama Chemical Co., Ltd. | Method for cooking fresh noodles in a microwave oven |
| US20030069206A1 (en) | 1998-07-10 | 2003-04-10 | Nichols Everett J. | Methods and kits for absorbing fat |
| PT1105123E (pt) | 1998-08-14 | 2004-08-31 | Hoffmann La Roche | Composicoes farmaceuticas contendo inibidores da lipase e quitosano |
| JP3371843B2 (ja) | 1999-02-25 | 2003-01-27 | 扶桑化学工業株式会社 | ロングライフ麺およびその製造方法 |
| US20020016307A1 (en) * | 1999-10-27 | 2002-02-07 | Mullins John Jason Gentry | Pharmaceutical composition with both a lipase inhibitor and a lipophilic polysaccharide and an improved method for treating adiposity |
| DE10054450A1 (de) | 2000-09-06 | 2002-03-28 | Guillermo Pasch Alonso | Verfahren zur Modifikation von Getreidemahlerzeugnissen, nach dem Verfahren hergestellte Produkte und deren Verwendung |
| JP5024807B2 (ja) | 2001-03-21 | 2012-09-12 | 独立行政法人水産総合研究センター | 血圧上昇の抑制組成物 |
| JP2003113089A (ja) * | 2001-10-04 | 2003-04-18 | Gotoo Corporation:Kk | 脂質蓄積性阻害およびコレステロール低下作用を有するキトサン含有製剤および飲食品 |
| JP2003238602A (ja) | 2002-02-20 | 2003-08-27 | Marino Forum 21 | 血糖値上昇抑制性物質 |
| ITRM20030127A1 (it) | 2003-03-24 | 2004-09-25 | Osvaldo Legnini | Composizione alimentare, pasta alimentare funzionale |
| KR100520007B1 (ko) * | 2003-05-19 | 2005-10-11 | 건 식 조 | 혈압 강하 기능을 가지는 키토산 함유 소금의 제조방법 |
| NZ549535A (en) | 2004-03-17 | 2010-11-26 | Novartis Ag | Use of aliskiren for treating renal and other disorders |
| CN1692782A (zh) | 2005-06-26 | 2005-11-09 | 苟春虎 | 降压好酸奶片 |
| RU2290185C1 (ru) | 2005-07-26 | 2006-12-27 | Дмитрий Николаевич Мясников | Композиция для нормализации липидного обмена и снижения массы тела и способ её получения |
-
2006
- 2006-03-03 IT IT000384A patent/ITMI20060384A1/it unknown
-
2007
- 2007-03-02 EP EP07726617A patent/EP1996207B1/en active Active
- 2007-03-02 MX MX2008011289A patent/MX2008011289A/es active IP Right Grant
- 2007-03-02 PL PL07726617T patent/PL1996207T3/pl unknown
- 2007-03-02 US US12/281,615 patent/US9050356B2/en active Active
- 2007-03-02 WO PCT/EP2007/052023 patent/WO2007099170A1/en not_active Ceased
- 2007-03-02 ES ES07726617T patent/ES2392551T3/es active Active
- 2007-03-02 JP JP2008557733A patent/JP5557451B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007099170A1 (en) | 2007-09-07 |
| EP1996207A1 (en) | 2008-12-03 |
| US9050356B2 (en) | 2015-06-09 |
| PL1996207T3 (pl) | 2013-01-31 |
| JP2009531306A (ja) | 2009-09-03 |
| JP5557451B2 (ja) | 2014-07-23 |
| ES2392551T3 (es) | 2012-12-11 |
| ITMI20060384A1 (it) | 2007-09-04 |
| EP1996207B1 (en) | 2012-08-08 |
| US20090258839A1 (en) | 2009-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7069490B2 (ja) | ユウリコマ・ロンギフォリア抽出物並びに免疫系の増強及び／又は刺激におけるその使用 | |
| CN107115414A (zh) | 用于预防及治疗第2型糖尿病的营养品组合 | |
| Arant et al. | Case studies of siblings with juxtaglomerular hyperplasia and secondary aldosteronism associated with severe azotemia and renal rickets—Bartter's syndrome or disease? | |
| CN101239069A (zh) | 可提供活性甲基或参与甲基转移的化合物的应用 | |
| CN112770749A (zh) | 双歧杆菌与黄连素联用对糖尿病前期和2型糖尿病的作用 | |
| CN118845809A (zh) | 一种黄酮衍生物防治肌少症的用途 | |
| JP4921681B2 (ja) | 予防薬剤 | |
| CN109157584A (zh) | 一种具有辅助降血脂功能的组合物及其制备方法和应用 | |
| CN102014944A (zh) | 利用复合药材的肥胖及代谢综合征的预防或治疗用组合物 | |
| MX2008011289A (es) | Composiciones que comprenden quitosano conveniente para tratamiento terapeutico integral o prevencion integral del sindrome metabolico. | |
| CN110292607B (zh) | 治疗高血压病并发左心室肥厚的中药组合物及制备方法 | |
| CN101850031B (zh) | 葛根异黄酮胶囊 | |
| Farquharson et al. | Pigment metabolism and destruction of blood in Addison's (pernicious) anemia | |
| CN105770087B (zh) | 一种治疗糖尿病、高脂血症、原发性高血粘度的蒙药组合物 | |
| CN104435220B (zh) | 治疗骨髓抑制的联合用药物 | |
| TWI921233B (zh) | 狼尾草萃出物及其製備方法與用途 | |
| CN119587646A (zh) | 一种中药组合物在制备降脂保肝药物中的应用 | |
| Belcaro et al. | Treatment of Dysmenorrhea with Physiologi-cal Modulators (A28): A Registry Study | |
| CN108904596A (zh) | 一种具有改善记忆力功效的组合物 | |
| JPH0371412B2 (https=) | ||
| TW202339724A (zh) | 一種血小板生成素受體激動劑的給藥方案 | |
| CN117256869A (zh) | 玉米低聚肽在制备改善肌肉衰减的特殊医学用途配方食品或药品中的用途 | |
| US20220079975A1 (en) | Method for mitigation of non-alcoholic fatty liver disease by use of a composition comprising small-molecule fucoidan and fucoxanthin | |
| CN121059761A (zh) | 一种玉米胚芽骨胶原粉及其在改善骨关节炎中的应用 | |
| Salom et al. | Vitamin C Mega Dose vs. Standard Dose in Smokers with Subclinical Hypovitaminosis C, A Controlled Randomised Clinical Trial–a short review. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights | ||
| FG | Grant or registration |